| Oct 28 2024 |
Exemptions from the Drug Supply Chain Security Act Enhanced Drug Distribution Security Requirements |
Epstein Becker & Green, P.C. |
| Oct 28 2024 |
From Opioids to Opt-Outs: Nonconsensual Third-Party Releases and the Aftermath of Purdue |
Proskauer Rose LLP |
| Oct 28 2024 |
Update: Federal and State Agencies Release Telehealth-Related Updates |
Bradley Arant Boult Cummings LLP |
| Oct 28 2024 |
Michigan Court Prohibits Sale of Illegal Marijuana in a Ruling Straight Out of “Duh” Magazine |
Bradley Arant Boult Cummings LLP |
| Oct 25 2024 |
Navigating the Buzz: How State Agencies Are Addressing Confusion Around Hemp and Low-Dose THC Beverages |
McDermott Will & Emery |
| Oct 25 2024 |
The Essentials—California Employment Law Update for 2025 |
K&L Gates LLP |
| Oct 25 2024 |
California Bans Online Sales of Flavored Tobacco Products Effective January 1, 2025 |
Keller and Heckman LLP |
| Oct 25 2024 |
Investors, Researchers, and Business Leaders Take Note: $110M Awarded to Advance Women’s Health |
Epstein Becker & Green, P.C. |
| Oct 25 2024 |
Food Labeling Update: Quality and Safety Dates – Clarifying “Best By” and “Use By” |
Sheppard, Mullin, Richter & Hampton LLP |
| Oct 24 2024 |
Registration Opens for NNI Webinar on Nanometrology Involving Big Data, AI, and Modeling |
Bergeson & Campbell, P.C. |
| Oct 24 2024 |
Texas Senate Committee Mulls Future of THC-Infused Beverages |
Bradley Arant Boult Cummings LLP |
| Oct 24 2024 |
This Week in 340B: October 15 – 21, 2024 |
McDermott Will & Emery |
| Oct 23 2024 |
Oregon Court Strikes Down Vape Packaging Law as Unconstitutional Violation of Free Speech |
Keller and Heckman LLP |
| Oct 23 2024 |
The Continued Evolution of Caremark Oversight Liability |
K&L Gates LLP |
| Oct 23 2024 |
GLP-1 Drugs: FDA Sued Over Removing Tirzepatide from the Drug Shortage List |
Foley & Lardner LLP |
| Oct 23 2024 |
Class Action Targets Naturally Flavored Claim in Cereal Bars with Malic Acid |
Keller and Heckman LLP |
| Oct 23 2024 |
Update: Federal Government Tells You to Believe What It Says, Not What It Does, in Case That Could Invalidate Federal Marijuana Prohibition |
Bradley Arant Boult Cummings LLP |
| Oct 23 2024 |
Health Plan Coverage Mandate for Over-the-Counter Contraception Proposed by Biden Administration |
Jackson Lewis P.C. |
| Oct 22 2024 |
EPA Issues Final Lead and Copper Rule Improvements with Far Reaching Lead Pipe Replacement Mandates |
Beveridge & Diamond PC |
| Oct 22 2024 |
FDA Partners With Purdue University to Study Salmonella Risks |
Keller and Heckman LLP |
| Oct 21 2024 |
Wait? My CBD Business May Be Racketeering? A Potential Existential Crisis We Have Been Warning About |
Bradley Arant Boult Cummings LLP |
| Oct 21 2024 |
EU Proposal for a Regulation on Packaging and Packaging Waste Nearing Adoption – The Highlights and Challenges Ahead |
Keller and Heckman LLP |
| Oct 19 2024 |
2024 Chemical Data Reporting Deadline Extended by EPA |
Beveridge & Diamond PC |
| Oct 18 2024 |
Supreme Court Declines to Hear “Willfulness” Case |
Polsinelli PC |
| Oct 18 2024 |
USDA’s ARS Develops Long-Term Roadmap for PFAS in U.S. Agriculture |
Bergeson & Campbell, P.C. |
| Oct 18 2024 |
FDA Issues Exemptions from November 27, 2024 Compliance Deadline for Updated DSCSA Requirements |
Polsinelli PC |
| Oct 18 2024 |
Survey on Carbon-Based Nanomaterials and Analytical Methods Closes November 1, 2024 |
Bergeson & Campbell, P.C. |
| Oct 18 2024 |
Trending in Telehealth: October 7 – 14, 2024 |
McDermott Will & Emery |
| Oct 18 2024 |
FDA’s Voluntary Sodium Reduction Goals: Key Takeaways from Recent Webinar |
Keller and Heckman LLP |
| Oct 18 2024 |
Teva Pharmaceuticals Agrees to Pay $450 Million to Resolve FCA Claims |
ArentFox Schiff LLP |
| Oct 17 2024 |
California Enacts Law to Standardize Date Labels |
Keller and Heckman LLP |
| Oct 17 2024 |
TSCA and the Food (and Food Packaging) Exemptions |
Keller and Heckman LLP |
| Oct 17 2024 |
This Week in 340B: October 8 – 14, 2024 |
McDermott Will & Emery |
| Oct 17 2024 |
New DEA Rule Expected to Extend Controlled Substance Telemedicine Prescribing Flexibilities Through 2025 |
Foley & Lardner LLP |
| Oct 17 2024 |
Federal Appeals Court Says Certain THC-O Products Are Legal Contrary to DEA Interpretation |
Bradley Arant Boult Cummings LLP |
